Literature DB >> 31959038

WIP1 dephosphorylation of p27Kip1 Serine 140 destabilizes p27Kip1 and reverses anti-proliferative effects of ATM phosphorylation.

Byung-Kwon Choi1,2, Kenichiro Fujiwara1, Tajhal Dayaram1, Yolanda Darlington1, Joshua Dickerson1, Margaret A Goodell2,3,4, Lawrence A Donehower1.   

Abstract

The phosphoinositide-3-kinase like kinases (PIKK) such as ATM and ATR play a key role in initiating the cellular DNA damage response (DDR). One key ATM target is the cyclin-dependent kinase inhibitor p27Kip1 that promotes G1 arrest. ATM activates p27Kip1-induced arrest in part through phosphorylation of p27Kip1 at Serine 140. Here we show that this site is dephosphorylated by the type 2C serine/threonine phosphatase, WIP1 (Wildtype p53-Induced Phosphatase-1), encoded by the PPM1D gene. WIP1 has been shown to dephosphorylate numerous ATM target sites in DDR proteins, and its overexpression and/or mutation has often been associated with oncogenesis. We demonstrate that wildtype, but not phosphatase-dead WIP1, efficiently dephosphorylates p27Kip1 Ser140 both in vitro and in cells and that this dephosphorylation is sensitive to the WIP1-specific inhibitor GSK 2830371. Increased expression of wildtype WIP1 reduces stability of p27Kip1 while increased expression of similar amounts of phosphatase-dead WIP1 has no effect on p27Kip1 protein stability. Overexpression of wildtype p27Kip1 reduces cell proliferation and colony forming capability relative to the S140A (constitutively non-phosphorylated) form of p27. Thus, WIP1 plays a significant role in homeostatic modulation of p27Kip1 activity following activation by ATM.

Entities:  

Keywords:  ATM; CDKN1B; PPM1D; Serine 140; WIP1; p27Kip1

Mesh:

Substances:

Year:  2020        PMID: 31959038      PMCID: PMC7100888          DOI: 10.1080/15384101.2020.1717025

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  35 in total

1.  Cip/Kip proteins: more than just CDKs inhibitors.

Authors:  Catherine Denicourt; Steven F Dowdy
Journal:  Genes Dev       Date:  2004-04-15       Impact factor: 11.361

2.  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

Authors:  Catherine C Coombs; Ahmet Zehir; Sean M Devlin; Ashwin Kishtagari; Aijazuddin Syed; Philip Jonsson; David M Hyman; David B Solit; Mark E Robson; José Baselga; Maria E Arcila; Marc Ladanyi; Martin S Tallman; Ross L Levine; Michael F Berger
Journal:  Cell Stem Cell       Date:  2017-08-10       Impact factor: 24.633

3.  Dephosphorylation of γ-H2AX by WIP1: an important homeostatic regulatory event in DNA repair and cell cycle control.

Authors:  Sung-Hwan Moon; Thuy-Ai Nguyen; Yolanda Darlington; Xiongbin Lu; Lawrence A Donehower
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

4.  Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.

Authors:  H Fujimoto; N Onishi; N Kato; M Takekawa; X Z Xu; A Kosugi; T Kondo; M Imamura; I Oishi; A Yoda; Y Minami
Journal:  Cell Death Differ       Date:  2005-11-25       Impact factor: 15.828

5.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.

Authors:  Dmitry V Bulavin; Oleg N Demidov; Shin'ichi Saito; Paivikki Kauraniemi; Crissy Phillips; Sally A Amundson; Concetta Ambrosino; Guido Sauter; Angel R Nebreda; Carl W Anderson; Anne Kallioniemi; Albert J Fornace; Ettore Appella
Journal:  Nat Genet       Date:  2002-05-20       Impact factor: 38.330

6.  The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.

Authors:  Xiongbin Lu; Dora Bocangel; Bonnie Nannenga; Hiroshi Yamaguchi; Ettore Appella; Lawrence A Donehower
Journal:  Mol Cell       Date:  2004-08-27       Impact factor: 17.970

7.  ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.

Authors:  Shuhei Matsuoka; Bryan A Ballif; Agata Smogorzewska; E Robert McDonald; Kristen E Hurov; Ji Luo; Corey E Bakalarski; Zhenming Zhao; Nicole Solimini; Yaniv Lerenthal; Yosef Shiloh; Steven P Gygi; Stephen J Elledge
Journal:  Science       Date:  2007-05-25       Impact factor: 47.728

8.  WIP1 phosphatase as a potential therapeutic target in neuroblastoma.

Authors:  Mark Richter; Tajhal Dayaram; Aidan G Gilmartin; Gopinath Ganji; Sandhya Kiran Pemmasani; Harjeet Van Der Key; Jason M Shohet; Lawrence A Donehower; Rakesh Kumar
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 9.  The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.

Authors:  Xiongbin Lu; Thuy-Ai Nguyen; Sung-Hwan Moon; Yolanda Darlington; Matthias Sommer; Lawrence A Donehower
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

10.  PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.

Authors:  Joanne I Hsu; Tajhal Dayaram; Ayala Tovy; Etienne De Braekeleer; Mira Jeong; Feng Wang; Jianhua Zhang; Timothy P Heffernan; Sonal Gera; Jeffrey J Kovacs; Joseph R Marszalek; Christopher Bristow; Yuanqing Yan; Guillermo Garcia-Manero; Hagop Kantarjian; George Vassiliou; P Andrew Futreal; Lawrence A Donehower; Koichi Takahashi; Margaret A Goodell
Journal:  Cell Stem Cell       Date:  2018-11-01       Impact factor: 24.633

View more
  3 in total

1.  PPM1D in Solid and Hematologic Malignancies: Friend and Foe?

Authors:  Linda Zhang; Joanne I Hsu; Margaret A Goodell
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

Review 2.  Regulation of p27Kip1 and p57Kip2 Functions by Natural Polyphenols.

Authors:  Gian Luigi Russo; Emanuela Stampone; Carmen Cervellera; Adriana Borriello
Journal:  Biomolecules       Date:  2020-09-13

3.  Knockdown of lncRNA HOXA-AS3 Suppresses the Progression of Atherosclerosis via Sponging miR-455-5p.

Authors:  Kui Chi; Jinwen Zhang; Huanhuan Sun; Yang Liu; Ye Li; Tao Yuan; Feng Zhang
Journal:  Drug Des Devel Ther       Date:  2020-09-09       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.